Remedium Lifecare Ltd
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
- Market Cap ₹ 112 Cr.
- Current Price ₹ 1.27
- High / Low ₹ 31.5 / 0.80
- Stock P/E 52.6
- Book Value ₹ 0.49
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 2.59 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 1.13%
- Earnings include an other income of Rs.10.8 Cr.
- Company has high debtors of 695 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 405 | |
| 406 | |
| Operating Profit | -1 |
| OPM % | -0% |
| 11 | |
| Interest | 5 |
| Depreciation | 0 |
| Profit before tax | 4 |
| Tax % | 51% |
| 2 | |
| EPS in Rs | 0.02 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -29% |
| 1 Year: | -96% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | 40 |
| Reserves | 4 |
| 1,141 | |
| 535 | |
| Total Liabilities | 1,720 |
| 0 | |
| CWIP | 0 |
| Investments | 0 |
| 1,720 | |
| Total Assets | 1,720 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| -1,135 | |
| 0 | |
| 1,136 | |
| Net Cash Flow | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 695 |
| Inventory Days | 247 |
| Days Payable | 459 |
| Cash Conversion Cycle | 483 |
| Working Capital Days | 38 |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Submission of newspaper publication intimating members for holding ensuing AGM for 2024-25 through VC/OAVM
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Q1 FY26 PAT ₹464.88 lakh; EBITDA +508%; oversubscribed ₹47.88 crore rights issue.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 13 Aug
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
13 Aug - Appointment of two non-executive independent directors approved via postal ballot on 12 Aug 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
11 Aug - Q1 FY26 PAT ₹464.88L, doubling FY25 profit; plans R&D expansion and global growth.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
Company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets